EICHORCondition: Lung Cancer, Nonsmall Cell · Sponsor: Imperial College London
Interested? Contact the study team ↓
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
REFINE-lung will test whether reduced pembrolizumab dose frequency after 6 months of standard treatment is safe and effective. Patients treated with 1st line pembrolizumab who are progression free and otherwise planning to continue therapy at 6 months will be initially randomised to control 6 weekly versus interventional 12 weekly therapy. If an interim analysis shows that the 12 weekly treatment is no less effective, subsequent patients will also be randomised to 9, 15 and 18 weekly treatment frequency arms. Patients who progress on a reduced frequency arm will be offered re-escalation to standard 6 weekly therapy.
This description comes directly from the study's public registry record.
Alex Baker · 020 7594 2180 · a.williams@imperial.ac.uk
Philip Badman · philip.badman@imperial.ac.uk
There is no obligation to join — the study team can answer your questions about taking part.
Always discuss trial participation with your own doctor first.
Inclusion Criteria: * Written informed consent prior to initiation of any study procedures and willingness and ability to comply with the study schedule * Any patient ≥18yrs who has received 6 months of pembrolizumab treatment with or without chemotherapy for advanced Non small cell lung cancer who is planned to continue immunotherapy treatment because of continued benefit. Exclusion Criteria: * Disease progression or not tolerating treatment at 6 months into therapy * Clinician does not intend to continue immunotherapy * Any patient with a synchronous primary cancer. This includes any new cancer diagnoses or relapse of previously treated cancer since starting pembrolizumab treatment. * Any patient currently receiving an investigational agent and/or using an investigational device or has participated in a study of an investigational agent and/or used an investigational device within 28 days of randomisation.
Reproduced word-for-word from the public registry record — the study team can answer questions about it.
| Royal Bournemouth Hospital | Bournemouth, United Kingdom | Recruiting |
| Royal Sussex County Hospital | Brighton, United Kingdom | Recruiting |
| Bristol Haematology and Oncology Centre | Bristol, United Kingdom | Recruiting |
| Queen's Hospital | Burton-on-Trent, United Kingdom | Recruiting |
| Cambridge University Hospitals NHS Foundation Trust | Cambridge, United Kingdom | Not Yet Recruiting |
| East Kent Hospitals University NHS Foundation Trust | Canterbury, United Kingdom | Recruiting |
| Velindre Cancer Centre | Cardiff, United Kingdom | Recruiting |
| Colchester Hospital | Colchester, United Kingdom | Recruiting |
| Royal Derby Hospital | Derby, United Kingdom | Recruiting |
| NHS Lothian | Edinburgh, United Kingdom | Recruiting |
| Royal Devon and Exeter Hospital | Exeter, United Kingdom | Recruiting |
| Beatson West of Scotland Cancer Centre | Glasgow, United Kingdom | Recruiting |
+ 25 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05085028